Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semagacestat in Alzheimer's Disease
NCT00594568Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2008
- Primary completion
- May 2011
- Modality
- Peptides, Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of semagacestat in Alzheimer's disease (AD), sponsored by Eli Lilly and Company. Started Mar 2008; status: completed.
02
Drugs
semagacestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00594568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00594568.